HDAC3 and diabetic cardiomyopathy: Xu et al. recently reported that HDAC3 inhibition with its selective inhibitor, RGFP966, increased the expression of MAP kinase phosphatase, DUSP 5 and prevented development of diabetic cardiomyopathy in Type 1 diabetes OVE26 mice, suggesting a therapeutic potential of HDAC3 inhibition in prevention of diabetic cardiomyopathy (10).